Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chantix in JAMA

This article was originally published in The Tan Sheet

Executive Summary

Pfizer's prescription therapy Chantix (varenicline) was "significantly more efficacious" for smoking cessation after 12- and 24-week periods than GlaxoSmithKline's Zyban (bupropion SR), according to a study published in the July 5 issue of the Journal of the American Medical Association. David Gonzales, PhD, Oregon Health & Science University, et al., randomized 1,025 healthy smokers 18 to 75 years old, with fewer than three months smoking abstinence. The groups were treated with one of the two drugs or placebo and took exhaled carbon monoxide tests to confirm abstinence. For weeks 9-12, 44% of the Chantix group stayed abstinent compared to 17.7% for the placebo group and 29.5% for the Zyban group. Chantix received approval in May (1"The Tan Sheet" May 15, 2005, In Brief)...

You may also be interested in...

Rx smoking cessation pill

FDA has approved Pfizer's smoking cessation drug Chantix (varenicline) for prescription use, the agency announces May 11. The drug, which Pfizer originally had intended to market as Champix, is the first nicotine agonist approved by FDA, and the first new Rx medication approved for smoking cessation in more than a decade, according to the firm. Varenicline works by binding to nicotine receptors in the brain, thereby "providing some nicotine effects to ease withdrawal symptoms and...blocking the effects of nicotine from cigarettes if [people] resume smoking," FDA states. Pfizer expects Chantix to launch in the second half of 2006. The firm has stated in the past that it will draw from its Nicorette experience when developing DTC ads for Chantix (1"The Tan Sheet" Feb. 9, 2004, p. 5)...

QUOTED. 10 April 2020. Shawn Patterson.

3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.

Bleach Mixtures Return To US Regulatory Radar Making COVID-19 Treatment Claims

FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts